BNP/CALL/ILLUMINA/180/0.1/20.12.24 | Delayed Deutsche Boerse AG 10:20:23 2024-06-03 am EDT | ||
| 0.18 EUR | +5.88% |
|
| 1 month | -73.02% | ||
| 3 months | -87.02% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ILLUMINA, INC.
| Date | Price | Change |
|---|---|---|
| 24-06-03 | 0.18 | +5.88% |
| 24-05-31 | 0.17 | +30.77% |
| 24-05-30 | 0.13 | -7.14% |
| 24-05-29 | 0.14 | -17.65% |
| 24-05-28 | 0.17 | -15.00% |
Delayed Quote Deutsche Boerse AG
Last update June 03, 2024 at 10:20 am EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ILLUMINA, INC. |
| Issuer | 
BNP Paribas
|
| WKN | PE9AYG |
| ISIN | DE000PE9AYG4 |
| Date issued | 2023-02-16 |
| Strike | 180 $ |
| Maturity | 2024-12-20 (200 Days) |
| Parity | 10 : 1 |
| Emission price | 5.64 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 8.54 € |
|---|---|
| Lowest since issue | 0.13 € |
| Spread | 0.04 € |
| Spread % | 18.18% |
Company Profile
Illumina, Inc. specializes in the development, manufacturing and marketing of integrated systems for the analysis of genetic variation and biological function. The group's products are for genomic research centers, pharmaceutical companies, university institutions, clinical research organizations, and biotechnology companies. Net sales break down by source of income as follows:
- product sales (84.1%): tools and instruments for sequencing, genotyping, genetic expression, etc.;
- sales of services (15.9%).
Net sales are distributed geographically as follows: the United States (52.4%), Americas (3.6%), Europe (25.3%), Asia/Pacific/Middle East/Africa (10.2%) and China/Taiwan/Hong Kong (8.5%).
Sector
-
Consensus: Illumina, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
104.3
USD
Average target price
155.5
USD
Spread / Average Target
+49.12%
- Stock Market
- Warrants
- Warrant
